ES2142864T3 - Procedimiento y medio de cultivo para la obtencion de celulas infectadas por un virus asociado a la esclerosis en placas. - Google Patents

Procedimiento y medio de cultivo para la obtencion de celulas infectadas por un virus asociado a la esclerosis en placas.

Info

Publication number
ES2142864T3
ES2142864T3 ES93908989T ES93908989T ES2142864T3 ES 2142864 T3 ES2142864 T3 ES 2142864T3 ES 93908989 T ES93908989 T ES 93908989T ES 93908989 T ES93908989 T ES 93908989T ES 2142864 T3 ES2142864 T3 ES 2142864T3
Authority
ES
Spain
Prior art keywords
culture
infected
sclerosis
plates
sep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908989T
Other languages
English (en)
Inventor
Herve Perron
Jean-Marie Seigneurin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9204322A external-priority patent/FR2689519B1/fr
Application filed by Biomerieux SA filed Critical Biomerieux SA
Application granted granted Critical
Publication of ES2142864T3 publication Critical patent/ES2142864T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PROCESO DE OBTENCION IN VITRO DE UN CULTIVO O LINEA CELULAR INFECTADA POR UNA CEPA VIRAL ASOCIADA A LA ESCLEROSIS EN PLACAS (SEP), SEGUN EL CUAL SE TOMA UNA MUESTRA DE UN INDIVIDUO AFECTADO DE SEP, SE CULTIVA DICHA MUESTRA EN UN MEDIO DE CULTIVO QUE FAVORECE EL CRECIMIENTO DE LAS CELULAS INFECTADAS, PARA OBTENER UN CULTIVO DE CELULAS PRIMARIAS INFECTADAS, Y SE CULTIVA EN SERIE, ES DECIR POR PASOS SUCESIVOS, EN DICHO MEDIO DE CULTIVO, UNA MUESTRA DEL CULTIVO DE CELULAS PRIMARIAS, O DE UN SUBCULTIVO DE ESTA ULTIMA, PARA OBTENER EL CULTIVO O LA DESCENDENCIA CELULAR INFECTADA POR UN VIRUS ASOCIADO A LA SEP, LA INVENCION SE CARACTERIZA QUE EL MEDIO DE CULTIVO CONTIENE ADEMAS UN ANTICUERPO ANTIINTERFERON BETA, O DIRIGIDO CONTRA UNA MOLECULA ANTIGENICAMENTE PROXIMA, JUGANDO UN PAPEL INHIBIDOR EN LA EXPRESION VIRAL, QUE PERMITE EXPRESAR DE MANERA PERSISTENTE Y PROPAGAN LA CEPA VIRAL EN EL CULTIVO O DESCENDENCIA CELULAR.
ES93908989T 1992-04-03 1993-04-02 Procedimiento y medio de cultivo para la obtencion de celulas infectadas por un virus asociado a la esclerosis en placas. Expired - Lifetime ES2142864T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9204322A FR2689519B1 (fr) 1992-04-03 1992-04-03 Procédé de culture in vitro de cellules infectées par un virus associé à la sclérose en plaques et lignées cellulaires obtenues.
FR9213443A FR2689520B1 (fr) 1992-04-03 1992-11-03 Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.

Publications (1)

Publication Number Publication Date
ES2142864T3 true ES2142864T3 (es) 2000-05-01

Family

ID=26229388

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908989T Expired - Lifetime ES2142864T3 (es) 1992-04-03 1993-04-02 Procedimiento y medio de cultivo para la obtencion de celulas infectadas por un virus asociado a la esclerosis en placas.

Country Status (9)

Country Link
US (3) US5650318A (es)
EP (2) EP0957162B1 (es)
AT (2) ATE188993T1 (es)
CA (1) CA2110703C (es)
DE (2) DE69327623T2 (es)
DK (1) DK0587873T3 (es)
ES (1) ES2142864T3 (es)
FR (1) FR2689520B1 (es)
WO (1) WO1993020188A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728585A1 (fr) * 1994-12-23 1996-06-28 Bio Merieux Virus msrv1 et agent pathogene et/ou infectant msrv2 associes a la sclerose en plaques et leurs constituants nucleiques
FR2715939B1 (fr) * 1994-02-04 1996-08-02 Bio Merieux Virus MSRV2 associé à la sclérose en plaques, et ses constituants nucléiques.
FR2715938B1 (fr) * 1994-02-04 1997-01-10 Bio Merieux Constituants nucléiques du virus MSRV1, associé à la sclérose en plaques.
US5871996A (en) * 1994-02-04 1999-02-16 Bio Merieux Retrovirus agents MSRV1 and MSRV2 associated with multiple sclerosis
FR2727428B1 (fr) * 1994-11-24 1997-04-30 Bio Merieux Virus msrv1 associe a la sclerose en plaques et ses constituants nucleiques
FR2715936B1 (fr) * 1994-02-04 1996-04-19 Bio Merieux Virus MSRV1 associé à la sclérose en plaques, et ses constituants nucléiques.
FR2715937A1 (fr) * 1994-02-04 1995-08-11 Bio Merieux Virus MSRV1 et MSRV2 associés ensemble à la sclérose en plaques et leurs constituants nucléiques.
FR2689520B1 (fr) 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
FR2716198B1 (fr) * 1994-02-15 1996-04-19 Bio Merieux Facteur cytotoxique tel qu'associé à la sclérose en plaques, sa détection et sa quantification.
FR2731356B1 (fr) * 1995-03-09 1997-04-30 Bio Merieux Virus msrv-1 et agent pathogene et/ou infectant msrv-2 associes a la polyarthrite rhumatoide
FR2737500B1 (fr) 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
EP0942987B1 (en) * 1996-11-26 2009-08-19 Bio Merieux Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
FR2762601B3 (fr) 1997-04-29 1999-06-04 Bio Merieux Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utilisations
ATE346153T1 (de) * 1997-07-07 2006-12-15 Bio Merieux Endogene retrovirale sequenzen, verwandten mit auto-immune krankheiten oder mit schwangerschaftsstörungen
FR2765588A1 (fr) 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
BR9804283B1 (pt) * 1998-03-18 2010-11-30 processo para a produção de flavivìrus em baixa densidade de células em cultura e processo para a produção de flavivìrus recombinante em baixa densidade de células em cultura.
FR2788784A1 (fr) * 1999-01-21 2000-07-28 Bio Merieux Fragment nucleique endogene associe a une maladie auto-immune, procede de marquage et reactif
EP1029917A1 (en) 1999-02-15 2000-08-23 Bio Merieux The LTR region of MSRV-1 and the proteins it encodes, and probes and methods for detecting MSRV-1 retrovirus
CA2403815A1 (en) * 2000-03-21 2001-09-27 Ms Research A/S An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980000412A1 (en) * 1978-08-24 1980-03-20 N Gilmour Pasteurellosis vaccines
US4311686A (en) * 1979-04-30 1982-01-19 The Immunology Development Corporation Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis
US4396600A (en) * 1980-12-18 1983-08-02 Gus Gallucci Adult schistosome worm-derived antigenic substance and method of obtaining same
US4388298A (en) 1982-07-14 1983-06-14 The United States Of America As Represented By The Secretary Of Agriculture Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4647773A (en) 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
NZ218050A (en) 1985-11-13 1989-05-29 Wistar Inst Test for the presence of htlv-1v
US4900553A (en) 1987-09-11 1990-02-13 Case Western Reserve University Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
EP0326395A2 (en) 1988-01-29 1989-08-02 City Of Hope Method of detecting and identifying certain viral sequences
FR2651581B1 (fr) 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5219837A (en) 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5158976A (en) 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
DK173091D0 (da) 1991-10-11 1991-10-11 Schleroseforeningen The Danish Biologisk materiale
FR2689521B1 (fr) 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
FR2689520B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
DK0642585T3 (da) 1992-05-18 2006-05-15 Genentech Inc Aktiviering af oligomeriserende receptorer ved anvendelse af fusionerede receptorligander
GB9310657D0 (en) 1993-05-24 1993-07-07 Univ London Retrovirus

Also Published As

Publication number Publication date
EP0957162B1 (fr) 2005-08-10
DE69333855T2 (de) 2006-09-28
DE69327623T2 (de) 2000-08-31
DE69327623D1 (de) 2000-02-24
ATE188993T1 (de) 2000-02-15
EP0587873B1 (fr) 2000-01-19
CA2110703A1 (fr) 1993-10-14
EP0957162A1 (fr) 1999-11-17
DK0587873T3 (da) 2000-07-17
DE69333855D1 (de) 2005-09-15
CA2110703C (fr) 2001-12-04
US6071736A (en) 2000-06-06
EP0587873A1 (fr) 1994-03-23
FR2689520B1 (fr) 1996-07-19
US6291225B1 (en) 2001-09-18
WO1993020188A1 (fr) 1993-10-14
FR2689520A1 (fr) 1993-10-08
ATE301707T1 (de) 2005-08-15
US5650318A (en) 1997-07-22

Similar Documents

Publication Publication Date Title
ES2142864T3 (es) Procedimiento y medio de cultivo para la obtencion de celulas infectadas por un virus asociado a la esclerosis en placas.
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
ES2078214T3 (es) Deteccion de virus mediante amplificacion e hibridacion.
CY1107121T1 (el) Ρυθμιση διαφοροποιησης αιματοποιητικων βλαστικων κυτταρων με τη χρηση ανθρωπινων μεσυγχυματικων βλαστικων κυτταρων
CL2004001483A1 (es) Procedimiento para producir una celula vegetal y un cultivo de estas, que son resistentes o tolerantes a un herbicida que inhibe a la glutamina sintetasa mediante la introduccion de un gen que codifica una acetil-transferasa; metodo para producir una
ES2112860T3 (es) Inmunoterapia adoptiva con interleukina-7.
EA200200604A1 (ru) Производство вакцин
YU45871B (sh) Polipeptid sa humanim imunointerferonskim (ifn-gama) svojstvima
ES2185811T3 (es) Metodo para detectar bacterias.
DK0891420T3 (da) Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus
DK1427817T3 (da) Formering af vira i cellekultur
ES2062887T3 (es) Secuencias de adn derivadas del genoma del papilomavirus hpv39, su aplicacion al diagnostico in vitro y a la produccion de preparado inmunogeno.
NL300020I1 (nl) Produktie van virus-antigenen.
ES2074968B1 (es) Nuevas cepas de pseudomonas aeruginosa atenuadas.
AR010583A1 (es) CULTIVO DE CÉLULAS DE UNA CEPA DERIVADA DE UNA CEPA PROGENITORA DE UNA ESPECIE DE NEOSPORA, VACUNA QUE LAS CONTIENE, Y COMPOSICIoN.
ES2097759T3 (es) Anticuerpos especificos para el dominio de fijacion de cd4 de hiv.
PT84640B (pt) Vector viral que contem um gene que codifica para uma das glicoproteinas (gp) do involucro do virus responsavel pela s.i.d.a. e anticorpos contra essas glicoproteinas
ES2052699T3 (es) Vacuna contra la gripe.
Brzin The localization of acetylcholinesterase in axonal membranes of frog nerve fibers.
ES8500995A1 (es) Un procedimiento para la preparacion de un vector de clonacion de adn recombinante.
ES2067916T3 (es) Matriz con celulas fijadas por adherencia y procedimiento de produccion de virus/antigenos de virus.
DK0592636T3 (da) Fremgangsmåde til fremstilling af en levedygtig cellekultur, der er inficeret med en med dissemineret sklerose forbundet vi
ATE10204T1 (de) Saccharose-mutase, immobilisierte saccharosemutase und verwendung von dieser immobilisierten saccharose-mutase zur herstellung von isomaltulose (6-0-alpha-d-glucopyranosido-d- fructose).
ES2085888T3 (es) Composicion de vacuna.
WO2024026362A3 (en) Pseudovirus based neutralization assay for evaluating vaccine immunogenicity

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 587873

Country of ref document: ES